MaxCyte, Inc. has announced the acquisition of SeQure Dx, a company specializing in assessing on-target and off-target gene editing for cell and gene therapies. This strategic move enhances MaxCyte's ...
ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance ...
LONGMONT, Colo. & WALTHAM, Mass.--(BUSINESS WIRE)--KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell ...
ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (MXCT),, a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of ...
News Medical on MSN
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments
MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results